Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 9/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19209472 | 0.90 | PIK3C2B (0.64) | PIK3C2BPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL19209431 | 0.88 | PIK3C2B (0.65) | PIK3C2BPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL19209459 | 0.82 | PIK3C2B (0.62) | PIK3C2BPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL19231013 | 0.82 | FYN (0.50) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL19209416 | 0.81 | PIK3CD (0.65) | PIK3C2BPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL19209494 | 0.79 | PIK3CG (0.50) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL681784 | 0.79 | PIK3C2B (1.00) | PIK3C2BPIK3CDPIK3CG | |
| SCHEMBL129487 | 0.79 | PIK3CD (0.72) | PIK3C2BPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL16701439 | 0.78 | PIK3CD (1.00) | PIK3C2BPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL682067 | 0.78 | PIK3C2B (0.66) | PIK3C2BPIK3CDPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411375-B1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2020-08-05 | — | — | EP | claimed |
| EP-3411375-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2018-12-12 | — | — | EP | claimed |
| WO-2017134053-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-10 | — | — | WO | claimed |
| EP-3411375-B1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2020-08-05 | — | — | EP | disclosed |
| EP-3411375-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134053-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134053-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226109-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-10 | — | — | US | disclosed |
| US-20170226109-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226109-A1 | PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | PI4KA, PI4KB, PI4K2B | PIK3C2B 10/4885PIK3CD 7/4885PIK3CG 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.